articleDeveloping broad-spectrum vaccines that target the heart of mutating viruses3 August 2022 | By Alexandre Le Vert (Osivax)Alexandre Le Vert, CEO and Co-Founder of Osivax, explores some evolving approaches to vaccine development that aim to counter the effects of virus mutation.